Abstract
Background
Patients with kidney failure suffer high mortality, and we currently lack markers for risk stratification for these patients. We carried out a quality control study of a modified aptamer assay (SomaScan v.4.0) that measures ~ 5000 proteins, in preparation for a larger study using this platform in cohorts with kidney failure.
Methods
Forty participants from the Cardiac, Endothelial Function and Arterial Stiffness in End-Stage Renal Disease (CERES study) were selected to analyze technical and short-term biological variability, orthogonal correlations and differential protein expression in plasma from patients who died during 2.5 year follow-up. Long-term (one year) variability was studied in 421 participants in the Chronic Renal Insufficiency Cohort. We evaluated 4849 aptamers (4607 unique proteins) using data formats including raw data and data formatted using Adaptive Normalization by Maximum Likelihood (ANML), an algorithm developed for SomaScan data in individuals with normal kidney function.
Results
In ANML format, median[IQR] intra-assay coefficient of variation (CV) was 2.38%[1.76, 3.40] and inter-assay CV was 7.38%[4.61, 13.12]. Short-term within-subject CV was 5.76% [3.35, 9.72]; long-term CV was 8.71%[5.91, 13.37]. Spearman correlations between aptamer and traditional assays for PTH, NT-proBNP, FGF-23 and CRP were all > 0.7. Fold-change (FC) in protein levels among non-survivors, significant after Bonferroni correction, included SVEP1 (FC[95% CI] 2.14 [1.62, 2.82]), keratocan (1.74 [1.40, 2.15]) and LanC-like protein 1 (0.56 [0.45, 0.70]). Compared to raw aptamer data, technical and short-term biological variability in paired samples was lower in ANML-formatted data. ANML formatting had minimal impact on orthogonal correlations with traditional assays or the associations of proteins with the phenotype of mortality.
Conclusions
SomaScan had excellent technical variability and low within-subject short-term variability. ANML formatting could facilitate comparison of biomarker results with other studies that utilize this format. We expect SomaScan to provide novel and reproducible information in patients with kidney failure on dialysis.
Funder
NHLBI
NIDDK
University of California, San Francisco
National Institutes of Health
Publisher
Public Library of Science (PLoS)
Reference36 articles.
1. USRDS. Volume 2, Chapter 5: Mortality in End-Stage Renal Disease in the United States 2018 [www.usrds.org/2018/view/v2_05.aspx.
2. USRDS. Volume 2, Chapter 1: Incidence and Prevalence of ESRD 2018.
3. USRDS. Volume 2, Chapter 9: Healthcare Expenditures for Persons with ESRD 2018 [www.usrds.org/2018/view/v2_09.aspx.
4. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients;K Kalantar-Zadeh;Kidney Int,2003
5. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review;MJ Sarnak;J Am Coll Cardiol,2019